Overview

PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
2020-03-17
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the safety of PD-1 knockout engineered T cells in treating metastatic non-small cell lung cancer. Blood samples will also be collected for research purposes.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Sichuan University
Collaborator:
Chengdu MedGenCell, Co., Ltd.
Treatments:
Cyclophosphamide
Interleukin-2
Criteria
Inclusion Criteria:

- Pathologically verified stage IV non-small cell lung cancer with measurable lesions
(On CT: longest diameter of tumoral lesion >=10 mm, shorted diameter of lymph node
>=15 mm; measurable lesions should not have been irradiated)

- Progressed after all standard treatment

- Performance score: 0-1

- Expected life span: >= 6 months

- Toxicities from prior treatment has resolved. Washout period is 4 weeks for
chemotherapy, and 2 weeks for targeted therapy

- Major organs function normally

- Women at pregnant ages should be under contraception

- Willing and able to provide informed consent

Exclusion Criteria:

- Pathology is mixed type

- Emergent treatment of tumor emergency is needed

- Poor vasculature

- Coagulopathy, or ongoing thrombolytics and/or anticoagulation

- Blood-borne infectious disease, e.g. hepatitis B

- History of mandatory custody because of psychosis or other psychological disease
inappropriate for treatment deemed by treating physician

- With other immune diseases, or chronic use of immunosuppressants or steroids

- Compliance cannot be expected

- Other conditions requiring exclusion deemed by physician